Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
A phase II trial of donanemab (700 mg for the first three doses and 1400 mg thereafter) or placebo intravenously every 4 weeks for up to 72 weeks in patients with early symptomatic Alzheimer's disease (AD) who had tau and amyloid deposition.
Primary outcome measures:
Change from baseline in the score on the Integrated Alzheimer’s Disease Rating Scale
The authors' conclusion was: In patients with early Alzheimer's disease, donanemab resulted in a better composite score for [cognition](brain://tRigU3JGMkeR4sVz__A1Uw/Co…